Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

Area of Science:

• Cardiovascular medicine
• Pharmacology
• Metabolic disorders

Background:

• Many patients on statin therapy do not reach target lipid levels.
• Combination therapy with complementary lipid-lowering agents can improve outcomes.
• Ezetimibe and simvastatin act via distinct pathways to reduce cholesterol.

Purpose of the Study:

• To evaluate the efficacy and safety of ezetimibe combined with simvastatin.
• To assess the impact on lipid profiles in patients with primary hypercholesterolemia.
• To compare combination therapy against simvastatin monotherapy.

Main Methods:

• Randomized controlled trial with 10 treatment groups.
• Patients received ezetimibe, simvastatin, ezetimibe plus simvastatin, or placebo.
• Primary endpoint: percentage reduction in low-density lipoprotein cholesterol (LDL-C).

Main Results:

• Ezetimibe plus simvastatin significantly reduced LDL-C, triglycerides (TG), and increased high-density lipoprotein cholesterol (HDL-C) versus simvastatin alone.
• Combination therapy yielded incremental LDL-C reductions of 13.8%, TG reductions of 7.5%, and HDL-C increases of 2.4%.
• Overall LDL-C reductions ranged from 44% to 57% with combination therapy.

Conclusions:

• Coadministration of ezetimibe with simvastatin provides significant incremental lipid-lowering benefits.
• The combination therapy demonstrated a safety profile comparable to simvastatin monotherapy.
• Ezetimibe enhances the lipid-modifying effects of simvastatin in hypercholesterolemia patients.